<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20241030001348&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20241030001348&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 30 Oct 2024 04:13:48 +0000</lastbuilddate>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471463/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this multi-centre IPTW analysis, patients with severe ischaemic cardiomyopathy undergoing revascularization by CABG rather than PCI showed improved long-term survival. However, future randomized controlled trials are needed to confirm the effect of any such benefits.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae672. doi: 10.1093/eurheartj/ehae672. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The optimal revascularization strategy in patients with ischaemic cardiomyopathy remains unclear with no contemporary randomized trial data to guide clinical practice. This study aims to assess long-term survival in patients with severe ischaemic cardiomyopathy revascularized by either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Australian and New Zealand Society of Cardiac and Thoracic Surgeons and Melbourne Interventional Group registries (from January 2005 to 2018), patients with severe ischaemic cardiomyopathy [left ventricular ejection fraction (LVEF) &lt;35%] undergoing PCI or isolated CABG were included in the analysis. Those with ST-elevation myocardial infarction and cardiogenic shock were excluded. The primary outcome was long-term National Death Index-linked mortality up to 10 years following revascularization. Risk adjustment was performed to estimate the average treatment effect using propensity score analysis with inverse probability of treatment weighting (IPTW).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 2042 patients were included, of whom 1451 patients were treated by CABG and 591 by PCI. Inverse probability of treatment weighting-adjusted demographics, procedural indication, coronary artery disease extent, and LVEF were well balanced between the two patient groups. After risk adjustment, patients treated by CABG compared with those treated by PCI experienced reduced long-term mortality [adjusted hazard ratio 0.59, 95% confidence interval (CI) 0.45-0.79, P = .001] over a median follow-up period of 4.0 (inter-quartile range 2.2-6.8) years. There was no difference between the groups in terms of in-hospital mortality [adjusted odds ratio (aOR) 1.42, 95% CI 0.41-4.96, P = .58], but there was an increased risk of peri-procedural stroke (aOR 19.6, 95% CI 4.21-91.6, P &lt; .001) and increased length of hospital stay (exponentiated coefficient 3.58, 95% CI 3.00-4.28, P &lt; .001) in patients treated with CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this multi-centre IPTW analysis, patients with severe ischaemic cardiomyopathy undergoing revascularization by CABG rather than PCI showed improved long-term survival. However, future randomized controlled trials are needed to confirm the effect of any such benefits.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471463/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39471463</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae672>10.1093/eurheartj/ehae672</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471463</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jason E Bloom</dc:creator>
<dc:creator>Sara Vogrin</dc:creator>
<dc:creator>Christopher M Reid</dc:creator>
<dc:creator>Andrew E Ajani</dc:creator>
<dc:creator>David J Clark</dc:creator>
<dc:creator>Melanie Freeman</dc:creator>
<dc:creator>Chin Hiew</dc:creator>
<dc:creator>Angela Brennan</dc:creator>
<dc:creator>Diem Dinh</dc:creator>
<dc:creator>Jenni Williams-Spence</dc:creator>
<dc:creator>Luke P Dawson</dc:creator>
<dc:creator>Samer Noaman</dc:creator>
<dc:creator>Derek P Chew</dc:creator>
<dc:creator>Ernesto Oqueli</dc:creator>
<dc:creator>Nicholas Cox</dc:creator>
<dc:creator>David McGiffin</dc:creator>
<dc:creator>Silvana Marasco</dc:creator>
<dc:creator>Peter Skillington</dc:creator>
<dc:creator>Alistair Royse</dc:creator>
<dc:creator>Dion Stub</dc:creator>
<dc:creator>David M Kaye</dc:creator>
<dc:creator>William Chan</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival</dc:title>
<dc:identifier>pmid:39471463</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae672</dc:identifier>
</item>
<item>
<title>Transcatheter correction of a rare combined anomalous pulmonary and systemic venous return in an adult</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae732. doi: 10.1093/eurheartj/ehae732. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39471415</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae732>10.1093/eurheartj/ehae732</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471415</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Grégoire Albenque</dc:creator>
<dc:creator>Clément Batteux</dc:creator>
<dc:creator>Sébastien Hascoët</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter correction of a rare combined anomalous pulmonary and systemic venous return in an adult</dc:title>
<dc:identifier>pmid:39471415</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae732</dc:identifier>
</item>
<item>
<title>Cardiac manifestation of lysosomal storage disorder</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae743. doi: 10.1093/eurheartj/ehae743. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39471408</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae743>10.1093/eurheartj/ehae743</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471408</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nikhil Singhania</dc:creator>
<dc:creator>A Shaheer Ahmed</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac manifestation of lysosomal storage disorder</dc:title>
<dc:identifier>pmid:39471408</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae743</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: RESHAPing potential treatment indications for functional mitral regurgitation in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae727. doi: 10.1093/eurheartj/ehae727. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39471406</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae727>10.1093/eurheartj/ehae727</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471406</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: RESHAPing potential treatment indications for functional mitral regurgitation in heart failure</dc:title>
<dc:identifier>pmid:39471406</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae727</dc:identifier>
</item>
<item>
<title>Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: The PROTECTED TAVR trial could not show that the use of CEP had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the US cohort but not in the OUS cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 29. doi: 10.1001/jamacardio.2024.4278. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Transcatheter aortic valve replacement (TAVR) is an established treatment option for many patients with severe symptomatic aortic stenosis; however, debris dislodged during the procedure can cause embolic stroke. The Sentinel cerebral embolic protection (CEP) device is approved for capture and removal of embolic material during TAVR but its efficacy has been debated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To explore regional differences in the association of CEP utilization with stroke outcomes in patients undergoing TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a prospective, postmarket, randomized clinical trial evaluating TAVR performed with or without the CEP took place at 51 hospitals in the US, Europe, and Australia from February 2020 to January 2022. Patients with symptomatic aortic stenosis treated with transfemoral TAVR were included. Randomization was stratified according to center, operative risk, and intended TAVR valve type. Patients were excluded if the left common carotid or brachiocephalic artery had greater than 70% stenosis or if the anatomy precluded placement of the CEP device. Data for this post hoc study were analyzed from August to October 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: TAVR with or without CEP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was the rate of all stroke events at hospital discharge or 72 hours post-TAVR, whichever came first. Neurological examinations were performed at baseline and postprocedure to identify stroke, disabling stroke, and other neurological outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The Stroke Protection With Sentinel During Transcatheter Aortic Valve Replacement (PROTECTED TAVR) trial enrolled and randomized 3000 patients (1803 [60.1%] male; mean [SD] age, 78.9 [7.8] years): 1833 in the US cohort (TAVR alone: 919, TAVR with CEP: 914) and 1167 patients in the outside the US (OUS) cohort (TAVR alone: 580, TAVR with CEP: 587). Patients in the US cohort were younger, more predominantly male, had a lower prevalence of atrial fibrillation, and had a higher prevalence of bicuspid aortic valve, diabetes, and peripheral vascular disease compared with the OUS cohort. In the main trial, the incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group, and there was no interaction by geographic region. In this post hoc analysis, patients treated with CEP in the US cohort exhibited a 50% relative risk reduction for overall stroke and a 73% relative risk reduction for disabling stroke compared to TAVR alone; a treatment effect on stroke risk reduction was not observed in the OUS cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: The PROTECTED TAVR trial could not show that the use of CEP had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the US cohort but not in the OUS cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics or procedural practices affect CEP efficacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04149535.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39471309</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4278>10.1001/jamacardio.2024.4278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471309</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Thomas E Waggoner</dc:creator>
<dc:creator>Samuel Horr</dc:creator>
<dc:creator>Juhana Karha</dc:creator>
<dc:creator>Lowell Satler</dc:creator>
<dc:creator>Robert C Stoler</dc:creator>
<dc:creator>Jorge Alvarez</dc:creator>
<dc:creator>Rahul Sakhuja</dc:creator>
<dc:creator>Lee MacDonald</dc:creator>
<dc:creator>Rodrigo Modolo</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39471309</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4278</dc:identifier>
</item>
<item>
<title>Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39470698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PEERLESS met its primary endpoint in favor of LBMT vs CDT in treatment of intermediate-risk PE. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural ICU utilization compared with CDT, with no difference in mortality or bleeding.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29. doi: 10.1161/CIRCULATIONAHA.124.072364. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There is a lack of randomized controlled trial (RCT) data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism (PE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PEERLESS is a prospective, multicenter, RCT that enrolled 550 intermediate-risk PE patients with right ventricular dilatation and additional clinical risk factors randomized 1:1 to treatment with large-bore mechanical thrombectomy (LBMT) or catheter-directed thrombolysis (CDT). The primary endpoint was a hierarchal win ratio (WR) composite of the following: 1) all-cause mortality, 2) intracranial hemorrhage, 3) major bleeding, 4) clinical deterioration and/or escalation to bailout, and 5) postprocedural intensive care unit (ICU) admission and length of stay, assessed at the sooner of hospital discharge or 7 days post-procedure. Assessments at the 24-hour visit included respiratory rate, mMRC dyspnea score, NYHA classification, right ventricle (RV)/left ventricle (LV) ratio reduction, and RV function. Endpoints through 30 days included total hospital stay, all-cause readmission, and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The primary endpoint occurred significantly less frequently with LBMT vs CDT (WR 5.01 [95% CI: 3.68-6.97]; <i>P</i>&lt;0.001). There were significantly fewer episodes of clinical deterioration and/or bailout (1.8% vs 5.4%; <i>P</i>=0.04) with LBMT vs CDT and less postprocedural ICU utilization (<i>P</i>&lt;0.001), including admissions (41.6% vs 98.6%) and stays >;24 hours (19.3% vs 64.5%). There was no significant difference in mortality, intracranial hemorrhage, or major bleeding between strategies, nor in a secondary WR endpoint including the first 4 components (WR 1.34 [95% CI: 0.78-2.35]; <i>P</i>=0.30). At the 24-hour visit, respiratory rate was lower for LBMT patients (18.3±3.3 vs 20.1±5.1; <i>P</i>&lt;0.001) and fewer had moderate to severe mMRC dyspnea scores (13.5% vs 26.4%; <i>P</i>&lt;0.001), NYHA classifications (16.3% vs 27.4%; <i>P</i>=0.002), and RV dysfunction (42.1% vs 57.9%; <i>P</i>=0.004). RV/LV ratio reduction was similar (0.32±0.24 vs 0.30±0.26; <i>P</i>=0.55). LBMT patients had shorter total hospital stays (4.5±2.8 vs 5.3±3.9 overnights; <i>P</i>=0.002) and fewer all-cause readmissions (3.2% vs 7.9%; <i>P</i>=0.03), while 30-day mortality was similar (0.4% vs 0.8%; <i>P</i>=0.62).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PEERLESS met its primary endpoint in favor of LBMT vs CDT in treatment of intermediate-risk PE. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural ICU utilization compared with CDT, with no difference in mortality or bleeding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39470698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39470698</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072364>10.1161/CIRCULATIONAHA.124.072364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39470698</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Wissam A Jaber</dc:creator>
<dc:creator>Carin F Gonsalves</dc:creator>
<dc:creator>Stefan Stortecky</dc:creator>
<dc:creator>Samuel Horr</dc:creator>
<dc:creator>Orestis Pappas</dc:creator>
<dc:creator>Ripal T Gandhi</dc:creator>
<dc:creator>Keith Pereira</dc:creator>
<dc:creator>Jay Giri</dc:creator>
<dc:creator>Sameer J Khandhar</dc:creator>
<dc:creator>Khawaja Afzal Ammar</dc:creator>
<dc:creator>David M Lasorda</dc:creator>
<dc:creator>Brian Stegman</dc:creator>
<dc:creator>Lucas Busch</dc:creator>
<dc:creator>David J Dexter Ii</dc:creator>
<dc:creator>Ezana M Azene</dc:creator>
<dc:creator>Nikhil Daga</dc:creator>
<dc:creator>Fakhir Elmasri</dc:creator>
<dc:creator>Chandra R Kunavarapu</dc:creator>
<dc:creator>Mark E Rea</dc:creator>
<dc:creator>Joseph S Rossi</dc:creator>
<dc:creator>Joseph Campbell</dc:creator>
<dc:creator>Jonathan Lindquist</dc:creator>
<dc:creator>Adam Raskin</dc:creator>
<dc:creator>Jason C Smith</dc:creator>
<dc:creator>Thomas M Tamlyn</dc:creator>
<dc:creator>Gabriel A Hernandez</dc:creator>
<dc:creator>Parth Rali</dc:creator>
<dc:creator>Torrey R Schmidt</dc:creator>
<dc:creator>Jeffrey T Bruckel</dc:creator>
<dc:creator>Juan C Camacho</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Samy Selim</dc:creator>
<dc:creator>Catalin Toma</dc:creator>
<dc:creator>Sukhdeep Singh Basra</dc:creator>
<dc:creator>Brian A Bergmark</dc:creator>
<dc:creator>Bhavraj Khalsa</dc:creator>
<dc:creator>David M Zlotnick</dc:creator>
<dc:creator>Jordan Castle</dc:creator>
<dc:creator>David J O'Connor</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>PEERLESS Committees and Investigators</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39470698</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072364</dc:identifier>
</item>
<item>
<title>Low ambient temperature and incident myocardial infarction with or without obstructive coronary arteries: a Chinese nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39468415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This nationwide study highlights the particular susceptibility of MINOCA patients to ambient low temperature compared with that of MI-CAD patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 28:ehae711. doi: 10.1093/eurheartj/ehae711. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Although non-optimum ambient temperature is a major non-traditional risk factor for acute myocardial infarction, there is no prior knowledge on whether non-optimum ambient temperature could differentially affect myocardial infarction with obstructive coronary artery disease (MI-CAD) and myocardial infarction with non-obstructive coronary arteries (MINOCA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Chinese Cardiovascular Association database-Chest Pain Center Registry, a nationwide, time-stratified, case-crossover investigation was conducted from 2015 to 2021. Meteorological data were obtained from an established satellite-based model, and daily exposures were assigned according to the onset of myocardial infarction in each patient. A conditional logistic regression model combined with distributed lag non-linear models (10 days) was used to estimate the exposure-response relationships.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 83 784 MINOCA patients and 918 730 MI-CAD patients were included. The risk of MINOCA and MI-CAD associated with low temperature occurred at lag 2 day and lasted to 1 week. Extremely low temperature was associated with a substantially greater odds ratio (OR) of MINOCA [OR 1.58, 95% confidence interval (CI) 1.31-1.90] than MI-CAD (unmatched: OR 1.32, 95% CI 1.23-1.43; equally matched by age and sex: OR 1.25, 95% CI 1.04-1.50), compared with the corresponding reference temperatures (30°C, 35°C, and 30°C). Stronger associations were observed for patients who were aged ≥65 years, female, or resided in the south. There was no significant difference for the impacts of high temperature on MINOCA and MI-CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This nationwide study highlights the particular susceptibility of MINOCA patients to ambient low temperature compared with that of MI-CAD patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39468415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39468415</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae711>10.1093/eurheartj/ehae711</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39468415</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jia Huang</dc:creator>
<dc:creator>Qinglin He</dc:creator>
<dc:creator>Yixuan Jiang</dc:creator>
<dc:creator>Jennifer Ming Jen Wong</dc:creator>
<dc:creator>Jianxuan Li</dc:creator>
<dc:creator>Jiangdong Liu</dc:creator>
<dc:creator>Ruochen Wang</dc:creator>
<dc:creator>Renjie Chen</dc:creator>
<dc:creator>Yuxiang Dai</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Low ambient temperature and incident myocardial infarction with or without obstructive coronary arteries: a Chinese nationwide study</dc:title>
<dc:identifier>pmid:39468415</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae711</dc:identifier>
</item>
<item>
<title>Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1412-1415. doi: 10.1161/CIRCULATIONAHA.124.069220. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466890</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069220>10.1161/CIRCULATIONAHA.124.069220</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466890</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Elisabetta Patorno</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials</dc:title>
<dc:identifier>pmid:39466890</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069220</dc:identifier>
</item>
<item>
<title>Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular resistance. Mixed CS can be broadly categorized as CS with at least 1 additional shock state....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1459-1468. doi: 10.1161/CIRCULATIONAHA.124.069508. Epub 2024 Oct 28.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular resistance. Mixed CS can be broadly categorized as <i>CS with at least 1 additional shock state</i>. Mixed CS states are now the second leading cause of shock in contemporary coronary intensive care units, but there is little high-quality evidence to guide routine care, and there are no standardized classification frameworks or well-established hemodynamic definitions. This primer summarizes the current epidemiology and proposes a classification framework and invasive hemodynamic parameters to guide categorization that could be applied to help better phenotype patients captured in registries and trials, as well as guide management of mixed CS states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466889</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069508>10.1161/CIRCULATIONAHA.124.069508</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466889</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Janek M Senaratne</dc:creator>
<dc:creator>Ann Gage</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management</dc:title>
<dc:identifier>pmid:39466889</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069508</dc:identifier>
</item>
<item>
<title>Centennial Collection: Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1395-1397. doi: 10.1161/CIRCULATIONAHA.124.070134. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466888</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11521109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">PMC11521109</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070134>10.1161/CIRCULATIONAHA.124.070134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466888</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sharlene M Day</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Centennial Collection: Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:39466888</dc:identifier>
<dc:identifier>pmc:PMC11521109</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070134</dc:identifier>
</item>
<item>
<title>A Rhythm Hidden in the Details</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466887/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1475-1477. doi: 10.1161/CIRCULATIONAHA.124.072049. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466887/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466887</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072049>10.1161/CIRCULATIONAHA.124.072049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466887</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Shasha Yu</dc:creator>
<dc:creator>Jingyu Jiao</dc:creator>
<dc:creator>Ming Liu</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Rhythm Hidden in the Details</dc:title>
<dc:identifier>pmid:39466887</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072049</dc:identifier>
</item>
<item>
<title>Oral Anticoagulation in Device Patients With Atrial High-Rate Episodes: Shared Decision-Making After ARTESIA and NOAH-AFNET-6</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1398-1400. doi: 10.1161/CIRCULATIONAHA.124.068018. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466886</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068018>10.1161/CIRCULATIONAHA.124.068018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466886</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Christine M Albert</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Oral Anticoagulation in Device Patients With Atrial High-Rate Episodes: Shared Decision-Making After ARTESIA and NOAH-AFNET-6</dc:title>
<dc:identifier>pmid:39466886</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068018</dc:identifier>
</item>
<item>
<title>Highlights From the Circulation Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1469-1474. doi: 10.1161/CIRCULATIONAHA.124.072348. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466885</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072348>10.1161/CIRCULATIONAHA.124.072348</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466885</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the Circulation Family of Journals</dc:title>
<dc:identifier>pmid:39466885</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072348</dc:identifier>
</item>
<item>
<title>Prevalence of Coronary Atherosclerosis in Female Masters Endurance Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466884/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1478-1480. doi: 10.1161/CIRCULATIONAHA.124.069484. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466884/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466884</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069484>10.1161/CIRCULATIONAHA.124.069484</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466884</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Efstathios Papatheodorou</dc:creator>
<dc:creator>Vincent L Aengevaeren</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:creator>Khaled AlFakih</dc:creator>
<dc:creator>Rebecca Kathryn Hughes</dc:creator>
<dc:creator>Ahmed Merghani</dc:creator>
<dc:creator>Christine K Kissel</dc:creator>
<dc:creator>Saad Fyyaz</dc:creator>
<dc:creator>Athanasios Bakalakos</dc:creator>
<dc:creator>Mathew G Wilson</dc:creator>
<dc:creator>Damini Dey</dc:creator>
<dc:creator>Gherardo Finocchiaro</dc:creator>
<dc:creator>Gemma Parry-Williams</dc:creator>
<dc:creator>Camilla Torlasco</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prevalence of Coronary Atherosclerosis in Female Masters Endurance Athletes</dc:title>
<dc:identifier>pmid:39466884</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069484</dc:identifier>
</item>
<item>
<title>Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466216/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PCD-CT exhibited excellent diagnostic performance for detecting obstructive CAD. Compared with patients undergoing conventional EID-CT, fewer patients were referred to ICA after PCD-CT, but those referred were more likely to undergo revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 23:S0735-1097(24)09956-X. doi: 10.1016/j.jacc.2024.10.069. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Photon-counting detector-computed tomography (PCD-CT) has emerged as a promising technology, offering improved spatial resolution.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to evaluate the clinical impact and diagnostic performance of PCD-CT vs conventional energy-integrating detector computed tomography (EID-CT) for obstructive coronary artery disease (CAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From 2022 to 2023, we retrospectively identified 7,833 consecutive patients who underwent clinically indicated coronary computed tomography angiography (CCTA) at a single center, with either PCD-CT (n = 3,876; NAEOTOM Alpha [Siemens Healthineers]) or EID-CT (n = 3,957; Revolution Apex 256 [GE HealthCare] or Aquilion ONE ViSION 320 [Canon Medical Systems]) scanners. Subsequent invasive coronary angiography (ICA) and percutaneous or surgical revascularization were performed as part of routine clinical care. Among those referred for ICA after coronary CTA, the presence of obstructive CAD in each vessel was determined by coronary CTA (severe stenosis on visual assessment per the Coronary Artery Disease Reporting and Data System) and ICA (≥50% diameter stenosis on quantitative coronary angiography) in a blinded fashion. The diagnostic performance of EID-CT and PCD-CT was compared by using quantitative coronary angiography as the reference standard.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients who underwent PCD-CT were less frequently referred to subsequent ICA than those undergoing EID-CT (9.9% vs 13.1%; P &lt; 0.001). Among those who underwent ICA, revascularization was more frequently performed in the PCD-CT group than in the EID-CT group (43.4% vs 35.5%; P = 0.02). In the vessel-level analysis (n = 1,686), specificity (98.0% vs 93.0%; P &lt; 0.001), positive predictive value (83.3% vs 63.0%; P = 0.002), and diagnostic accuracy (97.2% vs 92.8%; P &lt; 0.001) were improved by PCD-CT. Sensitivity (90.9% vs 90.7%; P = 0.95) and negative predictive value (98.9% vs 98.7%; P = 0.83) for obstructive CAD were similar between the PCD-CT and EID-CT groups, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PCD-CT exhibited excellent diagnostic performance for detecting obstructive CAD. Compared with patients undergoing conventional EID-CT, fewer patients were referred to ICA after PCD-CT, but those referred were more likely to undergo revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466216/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466216</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.069>10.1016/j.jacc.2024.10.069</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466216</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Koshiro Sakai</dc:creator>
<dc:creator>Doosup Shin</dc:creator>
<dc:creator>Mandeep Singh</dc:creator>
<dc:creator>Sarah Malik</dc:creator>
<dc:creator>Ali Dakroub</dc:creator>
<dc:creator>Zainab Sami</dc:creator>
<dc:creator>Jonathan Weber</dc:creator>
<dc:creator>J Jane Cao</dc:creator>
<dc:creator>Roosha Parikh</dc:creator>
<dc:creator>Lu Chen</dc:creator>
<dc:creator>Fernando Sosa</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Jeffrey W Moses</dc:creator>
<dc:creator>Richard A Shlofmitz</dc:creator>
<dc:creator>Carlos Collet</dc:creator>
<dc:creator>Evan Shlofmitz</dc:creator>
<dc:creator>Allen Jeremias</dc:creator>
<dc:creator>Omar K Khalique</dc:creator>
<dc:creator>Ziad A Ali</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease</dc:title>
<dc:identifier>pmid:39466216</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.069</dc:identifier>
</item>
<item>
<title>Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results from a Large European Real-World Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39466215/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The PASCAL system effectively treats severe TR in high-risk patients, offering sustained TR reduction and significant clinical improvements at 1-year follow-up. (PASCAL for Tricuspid Regurgitation-a European registry [PASTE]; NCT05328284).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 24:S0735-1097(24)09955-8. doi: 10.1016/j.jacc.2024.10.068. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tricuspid valve transcatheter edge-to-edge repair has emerged as a valuable treatment option for patients with severe tricuspid regurgitation (TR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to investigate the safety and effectiveness of the PASCAL transcatheter valve repair system in treating severe TR in a real-world patient population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PASTE (PASCAL for Tricuspid Regurgitation-a European registry) study is an investigator-initiated, multicenter, retrospective, and prospective observational cohort analysis conducted across 16 European heart valve centers including consecutive patients treated with the PASCAL transcatheter valve repair system from February 2019 to November 2023. Echocardiographic assessments were performed at baseline, discharge, and follow-up, and were subjected to centralized analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 1,059 high-risk patients (mean age 79 ± 9 years; 53% female; TRI-SCORE risk 23% ± 18%; 87% NYHA functional class III/IV) with multiple comorbidities. Severe or higher graded TR was observed in 96% of patients. Intraprocedural success according to Tricuspid Valve Academic Research Consortium criteria was achieved in 85%, and TR reduced to ≤moderate in 87%. Independent predictors for a postprocedure residual TR of >;moderate were coaptation gaps ≥8 mm (OR: 1.67; 95% CI: 1.03-2.72; P = 0.038), tenting height ≥10 mm (OR: 2.18; CI: 1.30-3.65; P = 0.003), the presence of a transvalvular lead (OR: 1.91; 95% CI: 1.19-3.05; P = 0.007), right ventricular dilatation >;42 mm (OR: 3.35; 95% CI: 1.37-9.1; P = 0.009) and massive/torrential TR at baseline (OR: 4.59; 95% CI: 2.35-8.96; P &lt; 0.001). At 1 year, 83% of patients showed ≤moderate TR. Significant clinical improvements included enhanced NYHA functional class (66% class I/II vs 17% at baseline; P &lt; 0.001). Patients treated with the first-generation PASCAL system (n = 570) and with the new PASCAL Precision system (n = 489) had similar clinical profiles and TR severity at baseline. However, the Precision cohort showed greater TR reduction to trace/mild (63% vs 49%; P &lt; 0.001), shorter procedure times (median 93 minutes [Q1-Q3: 69-130 minutes] vs 120 minutes [Q1-Q3: 82-165 minutes]; P &lt; 0.001), and higher clinical success rates according to the Tricuspid Valve Academic Research Consortium at 30 days and 1 year (87% vs 81% [P = 0.021] and 56% vs 50% [P = 0.044], respectively). Higher center experience (≥21 patients/year) resulted in higher intraprocedural and clinical success.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The PASCAL system effectively treats severe TR in high-risk patients, offering sustained TR reduction and significant clinical improvements at 1-year follow-up. (PASCAL for Tricuspid Regurgitation-a European registry [PASTE]; NCT05328284).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39466215/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39466215</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.068>10.1016/j.jacc.2024.10.068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39466215</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Mirjam G Wild</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Sebastian Rosch</dc:creator>
<dc:creator>Felix Rudolph</dc:creator>
<dc:creator>Björn Goebel</dc:creator>
<dc:creator>Benedikt Köll</dc:creator>
<dc:creator>Philipp von Stein</dc:creator>
<dc:creator>Wolfgang Rottbauer</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Harald Beucher</dc:creator>
<dc:creator>Martin Kraus</dc:creator>
<dc:creator>Mohammad Kassar</dc:creator>
<dc:creator>Tobias Geisler</dc:creator>
<dc:creator>Andreas Rück</dc:creator>
<dc:creator>Joao Ferreira-Martins</dc:creator>
<dc:creator>Stefan Toggweiler</dc:creator>
<dc:creator>Paula Sagmeister</dc:creator>
<dc:creator>Dirk Westermann</dc:creator>
<dc:creator>Thomas J Stocker</dc:creator>
<dc:creator>Ludwig T Weckbach</dc:creator>
<dc:creator>Michael Näbauer</dc:creator>
<dc:creator>Magnus Settergren</dc:creator>
<dc:creator>Sam Dawkins</dc:creator>
<dc:creator>Tobias Kister</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Marc Vorpahl</dc:creator>
<dc:creator>Mathias H Konstandin</dc:creator>
<dc:creator>Peter Lüdike</dc:creator>
<dc:creator>Mirjam Keßler</dc:creator>
<dc:creator>Christos Iliadis</dc:creator>
<dc:creator>Daniel Kalbacher</dc:creator>
<dc:creator>Philip Lauten</dc:creator>
<dc:creator>Muhammed Gerçek</dc:creator>
<dc:creator>Christian Besler</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>PASTE Investigators</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results from a Large European Real-World Registry</dc:title>
<dc:identifier>pmid:39466215</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.068</dc:identifier>
</item>
<item>
<title>CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39465245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our proof-of-concept study demonstrates the therapeutic potential of FAP CAR-Ms in alleviating myocardial I/R and potentially opens new avenues for the treatment of a range of heart diseases that include a fibrotic phenotype.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 28. doi: 10.1161/CIRCRESAHA.124.325212. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Given the growing acknowledgment of the detrimental effects of excessive myocardial fibrosis on pathological remodeling after myocardial ischemia-reperfusion injury (I/R), targeting the modulation of myocardial fibrosis may offer protective and therapeutic advantages. However, effective clinical interventions and therapies that target myocardial fibrosis remain limited. As a promising chimeric antigen receptor (CAR) cell therapy, whether CAR macrophages (CAR-Ms) can be used to treat I/R remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The expression of FAP (fibroblast activation protein) was studied in mouse hearts after I/R. FAP CAR-Ms were generated to target FAP-expressing cardiac fibroblasts in mouse hearts after I/R. The phagocytosis activity of FAP CAR-Ms was tested in vitro. The efficacy and safety of FAP CAR-Ms in treating I/R were evaluated in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: FAP was significantly upregulated in activated cardiac fibroblasts as early as 3 days after I/R. Upon demonstrating their ability to engulf FAP-overexpressing fibroblasts, we intravenously administered FAP CAR-Ms to mice at 3 days after I/R and found that FAP CAR-Ms significantly improved cardiac function and reduced myocardial fibrosis in mice after I/R. No toxicities associated with FAP CAR-Ms were detected in the heart or other organs at 2 weeks after I/R. Finally, we found that FAP CAR-Ms conferred long-term cardioprotection against I/R.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our proof-of-concept study demonstrates the therapeutic potential of FAP CAR-Ms in alleviating myocardial I/R and potentially opens new avenues for the treatment of a range of heart diseases that include a fibrotic phenotype.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39465245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39465245</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325212>10.1161/CIRCRESAHA.124.325212</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39465245</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiawan Wang</dc:creator>
<dc:creator>Heng Du</dc:creator>
<dc:creator>Wanrun Xie</dc:creator>
<dc:creator>Jinmiao Bi</dc:creator>
<dc:creator>Hao Zhang</dc:creator>
<dc:creator>Xu Liu</dc:creator>
<dc:creator>Yuhan Wang</dc:creator>
<dc:creator>Shaolong Zhang</dc:creator>
<dc:creator>Anhua Lei</dc:creator>
<dc:creator>Chuting He</dc:creator>
<dc:creator>Hailong Yuan</dc:creator>
<dc:creator>Jiahe Zhang</dc:creator>
<dc:creator>Yujing Li</dc:creator>
<dc:creator>Pengfei Xu</dc:creator>
<dc:creator>Siqi Liu</dc:creator>
<dc:creator>Yanan Zhou</dc:creator>
<dc:creator>Jianghua Shen</dc:creator>
<dc:creator>Jingdong Wu</dc:creator>
<dc:creator>Yihong Cai</dc:creator>
<dc:creator>Chaofan Yang</dc:creator>
<dc:creator>Zeya Li</dc:creator>
<dc:creator>Yingxin Liang</dc:creator>
<dc:creator>Yang Zhao</dc:creator>
<dc:creator>Jin Zhang</dc:creator>
<dc:creator>Moshi Song</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury</dc:title>
<dc:identifier>pmid:39465245</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325212</dc:identifier>
</item>
<item>
<title>Association Between Delay to First Shock and Successful First-Shock Ventricular Fibrillation Termination in Patients With Witnessed Out-of-Hospital Cardiac Arrest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462804/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Every minute of delay to first shock was associated with a significantly lower proportion of VF termination and return of organized rhythm. This may explain the worse outcomes in patients with a long delay to defibrillation. Reducing the time interval from emergency call to first shock to ≤6 minutes could be considered a key performance indicator of the chain of survival.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.069834. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with out-of-hospital cardiac arrest who present with an initial shockable rhythm, a longer delay to the first shock decreases the probability of survival, often attributed to cerebral damage. The mechanisms of this decreased survival have not yet been elucidated. Estimating the probability of successful defibrillation and other factors in relation to the time to first shock may guide prehospital care systems to implement policies that improve patient survival by decreasing time to first shock.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with a witnessed out-of-hospital cardiac arrest and ventricular fibrillation (VF) as an initial rhythm were included using the prospective ARREST registry (Amsterdam Resuscitation Studies). Patient and resuscitation data, including time-synchronized automated external defibrillator and manual defibrillator data, were analyzed to determine VF termination at 5 seconds after the first shock. Delay to first shock was defined as the time from initial emergency call until the first shock by any defibrillator. Outcomes were the proportion of VF termination, return of organized rhythm, transportation with return of spontaneous circulation, and survival to discharge, all in relation to the delay to first shock. A Poisson regression model with robust standard errors was used to estimate the association between delay to first shock and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3723 patients, the proportion of VF termination declined from 93% when the delay to first shock was &lt;6 minutes to 75% when that delay was >;16 minutes (<i>P</i><sub>trend</sub>&lt;0.001). Every additional minute in VF from emergency call was associated with 6% higher probability of failure to terminate VF (adjusted relative risk, 1.06 [95% CI, 1.04-1.07]), 4% lower probability of return of organized rhythm (adjusted relative risk, 0.96 [95% CI, 0.95-0.98]), and 6% lower probability of surviving to discharge (adjusted relative risk, 0.94 [95% CI, 0.93-0.95]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Every minute of delay to first shock was associated with a significantly lower proportion of VF termination and return of organized rhythm. This may explain the worse outcomes in patients with a long delay to defibrillation. Reducing the time interval from emergency call to first shock to ≤6 minutes could be considered a key performance indicator of the chain of survival.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462804/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39462804</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069834>10.1161/CIRCULATIONAHA.124.069834</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462804</guid>
<pubDate>Mon, 28 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Remy Stieglis</dc:creator>
<dc:creator>Bas J Verkaik</dc:creator>
<dc:creator>Hanno L Tan</dc:creator>
<dc:creator>Rudolph W Koster</dc:creator>
<dc:creator>Hans van Schuppen</dc:creator>
<dc:creator>Christian van der Werf</dc:creator>
<dc:date>2024-10-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association Between Delay to First Shock and Successful First-Shock Ventricular Fibrillation Termination in Patients With Witnessed Out-of-Hospital Cardiac Arrest</dc:title>
<dc:identifier>pmid:39462804</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069834</dc:identifier>
</item>
<item>
<title>Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462482/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The derivation cohort comprised 29,188 patients undergoing PCI, of whom 1136 (3.9%) had a Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at 1 year, from four contemporary real-world registries and the XIENCE V USA trial. The PRECISE-DAPT score was refitted with a Fine-Gray model in the derivation cohort and extended with the ARC-HBR criteria. The primary outcome was BARC 3 or 5 bleeding within 1 year. Independent predictors of BARC 3 or 5 bleeding were selected at multivariable analysis (p&lt;0.01). The discrimination of the score was internally assessed with apparent validation and cross-validation. The score was externally validated in 4578 patients from the MASTER DAPT trial and 5970 patients from the STOPDAPT-2 total cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The PRECISE-HBR score (age, estimated glomerular filtration rate, hemoglobin, white-blood-cell count, previous bleeding, oral anticoagulation, and ARC-HBR criteria) showed an area under the curve (AUC) for 1-year BARC 3 or 5 bleeding of 0.73 (95% CI, 0.71-0.74) at apparent validation, 0.72 (95% CI, 0.70-0.73) at cross-validation, 0.74 (95% CI, 0.68-0.80) in the MASTER DAPT, and 0.73 (95% CI, 0.66-0.79) in the STOPDAPT-2, with superior discrimination than the PRECISE-DAPT (cross-validation: Δ AUC, 0.01; p=0.02; MASTER DAPT: Δ AUC, 0.05; p=0.004; STOPDAPT-2: Δ AUC, 0.02; p=0.20) and other risk scores. In the derivation cohort, a cut-off of 23 points identified 11,414 patients (39.1%) with a 1-year BARC 3 or 5 bleeding risk ≥4%. An alternative version of the score, including acute myocardial infarction on admission instead of white-blood-cell count, showed similar predictive ability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462482/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39462482</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072009>10.1161/CIRCULATIONAHA.124.072009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462482</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Felice Gragnano</dc:creator>
<dc:creator>David van Klaveren</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Mitchell W Krucoff</dc:creator>
<dc:creator>Sergio Raposeiras-Roubän</dc:creator>
<dc:creator>Jurriën M Ten Berg</dc:creator>
<dc:creator>Sergio Leonardi</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Noé Corpataux</dc:creator>
<dc:creator>Alessandro Spirito</dc:creator>
<dc:creator>James B Hermiller</dc:creator>
<dc:creator>Emad Abu-Assi</dc:creator>
<dc:creator>Dean Chan Pin Yin</dc:creator>
<dc:creator>Jaouad Azzahhafi</dc:creator>
<dc:creator>Claudio Montalto</dc:creator>
<dc:creator>Marco Galazzi</dc:creator>
<dc:creator>Sarah Bär</dc:creator>
<dc:creator>Raminta Kavaliauskaite</dc:creator>
<dc:creator>Fabrizio D'Ascenzo</dc:creator>
<dc:creator>Gaetano M De Ferrari</dc:creator>
<dc:creator>Hirotoshi Watanabe</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Paolo Calabrò</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Philip Urban</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention</dc:title>
<dc:identifier>pmid:39462482</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072009</dc:identifier>
</item>
<item>
<title>Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Physiological stenosis severity, as measured by FFR and iFR, predicts placebo-controlled angina relief from PCI. Invasive coronary physiology can be used to target PCI to those patients who are most likely to experience benefit.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072281. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina (ORBITA-2) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable coronary artery disease (CAD). Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are often used to guide PCI, however their ability to predict placebo-controlled angina improvement is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants with angina, ischemia, and stable CAD were enrolled and antianginal medications were stopped. Participants reported angina episodes daily for 2 weeks using the ORBITA-app. At the research angiogram, FFR and iFR were measured. After sedation and auditory isolation, participants were randomized to PCI or placebo, before entering a 12-week blinded follow-up phase with daily angina reporting. The ability of FFR and iFR, analyzed as continuous variables, to predict the placebo-controlled effect of PCI, was tested using Bayesian proportional odds modelling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Invasive physiology data were available in 279 patients (140 PCI and 139 placebo). The median (IQR) age was 65 years (59.0 to 70.5) and 223 (79.9%) were male. Median FFR was 0.60 (0.46 to 0.73) and median iFR was 0.76 (0.50 to 0.86). The lower the FFR or iFR, the greater the placebo-controlled improvement with PCI across all endpoints. There was strong evidence that a patient with an FFR at the lower quartile would have a greater placebo-controlled improvement in angina symptom score with PCI than a patient at the upper quartile (FFR 0.46 vs. 0.73: OR 2.01, 95% CrI 1.79 to 2.26, Pr(Interaction)>;99.9%). Similarly, there was strong evidence that a patient with an iFR at the lower quartile would have a greater placebo controlled improvement in angina symptom score with PCI than a patient with an iFR at the upper quartile (iFR 0.50 vs. 0.86: OR 2.13, 95% CrI 1.87 to 2.45, Pr(Interaction) >;99.9%). The relationship between benefit and physiology was seen in both Rose angina and Rose nonangina.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Physiological stenosis severity, as measured by FFR and iFR, predicts placebo-controlled angina relief from PCI. Invasive coronary physiology can be used to target PCI to those patients who are most likely to experience benefit.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39462291</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072281>10.1161/CIRCULATIONAHA.124.072281</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462291</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael J Foley</dc:creator>
<dc:creator>Christopher A Rajkumar</dc:creator>
<dc:creator>Fiyyaz Ahmed-Jushuf</dc:creator>
<dc:creator>Florentina Simader</dc:creator>
<dc:creator>Shayna Chotai</dc:creator>
<dc:creator>Henry Seligman</dc:creator>
<dc:creator>Krzysztof Macierzanka</dc:creator>
<dc:creator>John R Davies</dc:creator>
<dc:creator>Thomas R Keeble</dc:creator>
<dc:creator>Peter O'Kane</dc:creator>
<dc:creator>Peter Haworth</dc:creator>
<dc:creator>Helen Routledge</dc:creator>
<dc:creator>Tushar Kotecha</dc:creator>
<dc:creator>Gerald Clesham</dc:creator>
<dc:creator>Rupert Williams</dc:creator>
<dc:creator>Jehangir Din</dc:creator>
<dc:creator>Sukhjinder S Nijjer</dc:creator>
<dc:creator>Nick Curzen</dc:creator>
<dc:creator>Manas Sinha</dc:creator>
<dc:creator>Ricardo Petraco</dc:creator>
<dc:creator>James Spratt</dc:creator>
<dc:creator>Sayan Sen</dc:creator>
<dc:creator>Graham D Cole</dc:creator>
<dc:creator>Frank E Harrell</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:creator>Darrel P Francis</dc:creator>
<dc:creator>Matthew J Shun-Shin</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>ORBITA-2 investigators</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease</dc:title>
<dc:identifier>pmid:39462291</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072281</dc:identifier>
</item>
<item>
<title>In Which Patients Will PCI Relieve Angina?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241030001348&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072466. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241030001348&v=2.18.0.post9+e462414">39462289</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072466>10.1161/CIRCULATIONAHA.124.072466</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462289</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>William F Fearon</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>In Which Patients Will PCI Relieve Angina?</dc:title>
<dc:identifier>pmid:39462289</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072466</dc:identifier>
</item>





























</channel>
</rss>